Medical cannabis as an Adjunctive Therapy in Schizophrenia

September 11, 2019
Schizophrenia.jpg

According to a study published in 2017 by the American Journal of Psychiatry, researchers have come to a conclusion that CBD can have a positive effect in patients with schizophrenia.

Studies about medical cannabis efficacy for Schizophrenia

The aim of this study was to investigate the safety and efficacy of CBD as an accompanying therapy for schizophrenia.  In a randomized (1:1 ratio) and double-blinded study, patients received either CBD (1000mg/day; N=43) or a placebo (N=45) as additional therapy to their existing antipsychotic medication for 6 weeks. Participants were assessed for effects of CBD before and after the treatment using the positive and negative Syndrom scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S).According to the study, the CBD group, compared to the placebo group, showed improvements in cognitive performance, functional range, and overall clinical impression of the patient. 

These results suggest that CBD may be a possible alternative in the treatment of schizophrenia.

Source: https://www.ncbi.nlm.nih.gov/pubmed/29241357

Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

footerlogos

OFFICES

CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg
Germany

CanPharma Portugal
Rua João Fernandes
Lavrador 1 – Sala 6 2825-
132 Vila Nova de Caparica
Portugal

REPRESENTATIVE OFFICES

Berlin
Neue Kantstraße 18
14057 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain